| A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis (NCT07719023) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2026-08-31 |
| A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection. (NCT07658534) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2026-03-03 |
| A Clinical Study of AK0610 (NCT06996704) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2024-02-29 |
| A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants (NCT06775405) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2024-02-29 |
| A Study of AK0529 in Adults Patients Hospitalized With RSV Infection (NCT06942299) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2023-07-20 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar (NCT05434897) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2022-07-08 |
| A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis (NCT05424887) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2022-07-01 |
| A Study of AK3280 in Chinese Healthy Volunteers (NCT04926116) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2021-06-09 |
| A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects (NCT04788017) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2021-03-24 |
| A Study of AK0529 in Chinese Infants Hospitalized With RSV (NCT04231968) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2020-09-22 |
| Anti-RSV Study in Chinese Patients (ASCENT) (NCT03699202) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2019-03-28 |
| A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529 (NCT03400995) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2018-01-05 |
| A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers (NCT03322800) | Shanghai Ark Biopharmaceutical Co., Ltd. | 2017-10-23 |